Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC-PCE study: PCE induction followed by cisplatin chemoradiation in unresectable locally advanced head and neck cancer
jRCTs031180358Active, not recruiting
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Proportion of chemoradiation completion. Started Jun 2014; status: active, not recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs031180358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180358.